Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring
Bruker and RECIPE are pioneering the high-throughput 'chrom-free' ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays
MUNICH, April 16, 2025--(BUSINESS WIRE)--Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays.
Financial details of the transaction were not disclosed. RECIPE has over 60 employees and continues to operate under the leadership of Managing Director Dr. Gernot Wolfram. With more than 40 years of experience, RECIPE is a highly respected, profitable company with 2024 revenues of more than fifteen million dollars.
The majority investment and strategic collaboration immediately enhances Bruker's capabilities in small molecule clinical diagnostic assays with RECIPE's ClinMASS® kits for Bruker's EVOQ® liquid chromatography triple-quadrupole mass spectrometers, as well as for LC-TQ-MS systems by other vendors. In addition, the companies are preparing the introduction of high-throughput, chromatography-free ('chrom-free') RECIPE ClinDART® kits running on flexible EVOQ-DART TQ⁺ systems that can easily switch between established LC-TQ-MS methods, and the novel high-throughput ClinDART workflows.
In chrom-free mode, the EVOQ-DART TQ⁺ offers higher throughput for multiplex assays without chromatography, while maintaining outstanding sensitivity and quantitation with triple-quad MS selectivity and multiple-reaction monitoring (MRM) capabilities. The ClinDART® platform also improves sustainability with a 95% reduction in solvent use, lower cost, and increased laboratory productivity. ClinDART® is complementary to RECIPE's ClinMASS LC-TQ assay portfolio and is expected to set new standards for high-throughput therapeutic drug monitoring (TDM), drugs of abuse screening, and other applications.
"Bruker's majority investment in RECIPE and our planned joint introduction of high-throughput ClinDART® assays represents a significant advancement in clinical mass spectrometry," said Dr. Gernot Wolfram, Managing Director at RECIPE. "Our unique collaboration on chrom-free, triple-quad TDM assays will allow RECIPE to provide clinical laboratories with a powerful new tool that complements our well-regarded ClinMASS® workflows on the EVOQ-DART TQ⁺. The additional high-throughput ClinDART methods reduce operating costs, and accelerate time-to-market for newly developed clinical diagnostics and multiplexed drugs of abuse screening assays."
Jeffrey Zonderman, Senior Vice President of Bruker Applied Mass Spectrometry, added: "We are excited to welcome RECIPE to the Bruker family. This majority investment aligns with our strategic vision for LC-TQ-MS assays, enhanced with novel chrom-free assays based on our proprietary DART® technology to lead in clinical research and regulated TDM markets. The RECIPE ClinMASS and novel ClinDART® assays, combined with LC or chrom-free EVOQ DART-TQ⁺ methods, are expected to offer unparalleled flexibility, throughput and cost-effectiveness."
Juergen Srega, Bruker CALID Group President, commented: "With the increasing importance of triple-quadrupole-based small molecule clinical diagnostics, our strategic collaboration with RECIPE is a pivotal step to democratize fast, efficient and sensitive assays for TDM, drugs of abuse screening and other clinical assays on a high-throughput, chrom-free TQ-MS platform."
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416762711/en/
Contacts
Investor Contact: Joe KostkaDirector, Investor RelationsBruker CorporationT: +1 (978) 313-5800E: Investor.Relations@bruker.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Liverpool Risk Losing Key Star Unless Contract Talks Progress Soon
Konate Contract Talks Stall as European Giants Circle Liverpool's determination to build a competitive squad under Arne Slot this summer could be overshadowed by uncertainty surrounding one of their most important players. According to Caught Offside, Ibrahima Konate's contract negotiations have hit a significant stumbling block, and with clubs like Real Madrid, Bayern Munich, PSG, and Al-Hilal circling, the clock is ticking. Advertisement 'Konate is reportedly demanding a weekly salary of around £200,000. However, Liverpool's management appears reluctant to meet those terms. If a new deal cannot be agreed by the end of the summer, the Merseyside club is prepared to offload the player for a fee in the region of €50–60 million,' the report states. Konate's current deal runs until 2026, but Liverpool have seen what can happen when renewal talks drift. The departure of Trent Alexander-Arnold to Madrid for free is still fresh and has made the Anfield hierarchy cautious. Concerns Over Another High-Profile Departure While Liverpool have made significant progress in refreshing the squad this summer, losing Konate would raise questions about defensive continuity, especially following the exits of key figures in previous windows. Advertisement The club reportedly views this transfer window as the cut-off point. They either extend his deal or accept an offer that reflects his value. Photo: IMAGO Sources close to the situation told Caught Offside that Liverpool are 'concerned' about a repeat of the scenario that saw Trent Alexander-Arnold depart for Real Madrid on a free transfer. That concern is justified. At 26, Konate is entering his peak years. He's physically dominant, comfortable on the ball, and one of the few defenders in the league capable of matching elite forwards stride for stride. Value vs. Risk in Liverpool's Summer Planning Konate has become central to Liverpool's backline since his arrival, forging a strong, if at times injury-interrupted, partnership with Virgil van Dijk. Slot will want to build around that stability, not risk it. Advertisement While the club has done well in early summer dealings, selling Konate would immediately shift priorities back to the heart of defence, a position where elite replacements are both scarce and expensive. Allowing him to enter the final two years of his contract without resolution would be a dangerous gamble. There's no shortage of interest, and once a player of Konate's calibre hits the market, clubs like PSG and Bayern are unlikely to wait for a discount. Room for Compromise Still Exists Liverpool's reluctance to meet £200,000 per week reflects their commitment to financial structure, a model that has served them well under FSG. But if they're to compete for the Premier League title again, keeping players like Konate becomes about more than wage policy. Photo: IMAGO Advertisement He remains 'one of the first names on the team sheet,' Caught Offside notes, and it's hard to imagine a version of Liverpool's title tilt without him. Still, compromise is essential. Whether it's through staggered incentives, loyalty bonuses, or a shorter-term extension, the club must find a way to avoid weakening the spine of the squad right before a crucial campaign. Our View – EPL Index Analysis For Liverpool fans, this feels like a familiar and frustrating scenario. A key player, loved by the fans, important to the team, yet somehow edging toward the exit due to financial deadlock. Konate isn't just a strong centre-back, he represents Liverpool's post-Klopp future. Young enough to grow under Slot, experienced enough to lead, and passionate enough to understand the demands of Anfield. Letting him go, even for €60 million, would send the wrong message at the wrong time. Advertisement The £200k wage figure is high, yes. But in the context of today's market, where defenders of similar quality are commanding huge fees and salaries, it's not outrageous. Van Dijk won't be around forever. Neither will Alisson. Keeping the next generation intact should be priority number one. If Konate walks because of a marginal wage dispute, fans will rightly question the club's long-term vision. It's not just about keeping good players, it's about showing that Liverpool remain a destination, not a stepping stone.
Yahoo
4 hours ago
- Yahoo
Trump wants one thing from the NATO summit. Europe is going to give it to him.
President Donald Trump wants one big thing from next week's NATO leader's summit — and European leaders are itching to give it to him. That doesn't guarantee the president will be satisfied. The 32-nation transatlantic military alliance will pledge to dramatically increase spending on defense to 5 percent of gross domestic product — 3.5 percent on hard military expenditures and 1.5 percent on more loosely defined defense-related efforts. The commitment, a watershed moment that could rebalance transatlantic security, will allow Trump, who's been demanding Europe pick up more of the burden for its own defense, a significant victory on the world stage. 'There is no way they would be going to 5 percent without Trump,' said one administration official, who was granted anonymity to share the president's views. 'So he sees this as a major win, and it is.' Trump intends to deliver a speech Wednesday at the summit's conclusion heralding the new spending pledge and his own catalytic role. But Trump's victory won't prevent him from pressuring countries to do even more, faster, which could prove difficult for some in the alliance. Spain, the NATO member with the lowest defense spending rate, isasking for an exemption from the new pledge and there is broad disagreement over the date by which this spending pledge is to be met. 'They're thinking of a timeline that is, frankly, a decade,' said Ivo Daalder, a former U.S. ambassador to NATO under President Barack Obama. 'Trump is probably thinking of a timeline that is by the end of this decade, if not sooner. That's where I think [the summit] can blow up.' While NATO allies are at odds over the details of the security pledge, there is broad agreement about the overriding importance of keeping Trump happy and maintaining a united front in The Hague, with Russia's war in Ukraine nowhere near an end and America's foreign policy focus increasingly shifting to Asia and the Middle East. In service of that aim, summit organizers have streamlined the meeting, reducing what is typically a two-day affair to 24 hours and focusing it around Trump's pledge, which has been negotiated ahead of time, and almost nothing else. 'He has to get credit for the 5 percent — that's why we're having the summit,' said one European defense official, granted anonymity to speak candidly about private government-level conversations. 'Everything else is being streamlined to minimize risk.' Asked about the pledge on Friday, Trump expressed support for allies spending more but added the 5 percent target shouldn't apply to the U.S., which is at 3.4 percent. Trump's saber-rattling toward Iran,teasing the possibility that the U.S. would join Israel's military campaign to destroy the country's nuclear development infrastructure and potentially topple the regime, has injected new uncertainty into a summit NATO officials had hoped to tightly script. But as of Friday, there were no formal plans to meet with allies to discuss the situation in the Middle East, though it could provide an opportunity for the president to tout the need for increased defense spending. NATO officials decided to pare down the agenda before Trump abruptly left the G7 halfway through the two-day program, a move that the administration official later attributed largely to his impatience with largely ceremonial multilateral meetings. In The Hague, as was the case in Canada, there will be no lengthy communique, only short statements about new commitments. The shortened NATO schedule allows for only two main events: a welcome dinner at the Dutch royal family's castle and a single meeting of the North Atlantic Council rather than the usual two or three, according to five people familiar with the planning. It is not clear if Ukrainian President Volodymyr Zelenskyy, invited only to the summit's opening dinner on Tuesday, will attend. And there won't be a meeting of NATO's Ukraine council in The Hague. It's another concession to the U.S., which, despite the urging of some allies to hold such a session, wasn't interested in heightening the focus on the war that Trump has been unable to resolve as he promised during last year's campaign. Paring down the summit is also a way for NATO allies to gloss over the persistent divide among countries about a critical detail of their pledge: how soon they'll be expected to reach the new spending benchmark. While the U.S. — and countries in eastern Europe already above the 3.5 percent benchmark — prefer a deadline of 2030, smaller countries, struggling to reach the new goals, want until 2032 or 2035. NATO Secretary General Mark Rutte floated 2032 as a compromise but, amid pushback from several smaller countries in recent days, the final wording of the pledge could give countries until 2035 to hit 5 percent, according to a European official familiar with private negotiations. 'For a lot of countries, this is the whole issue,' the European defense official continued. 'It's not so difficult to say, 'Yes, we will, we will agree.' But it's very difficult to find the right path and to actually find the budget for that path. So that's why nobody, nobody wants to talk about it anymore.' It's possible that the matter of the timeline won't be resolved during the summit. 'The priority is really to announce success in The Hague,' said another European official, also granted anonymity because they were not authorized to speak publicly. 'The longer-term perspective is less important.' NATO officials and European allies are determined to avoid a repeat of the 2018 summit in Brussels, which Trump upended by threatening to withdraw the U.S. from the alliance altogether if other countries didn't get serious about reaching the 2 percent spending benchmark they'd agreed to four years earlier. More than anything since, Russia's invasion of Ukraine in February 2022 altered defense calculations for Europe, pushing several countries to meet the 2 percent threshold and prompting Sweden and Finland, after decades of neutrality, to join the alliance. With the war ongoing and Trump back in office, the increased spending commitments are at least as much about Europe's long-term defense as they are appeasing the unpredictable Trump. In his speech this week at London's Chatham House, Rutte began to publicly lay out NATO's new capability targets — the amount of military equipment needed to implement a defense plan against a potential Russian attack — that defense ministers agreed to earlier this month. The alliance, Rutte said, needs 'a 400 percent increase in air and missile defence … thousands more armored vehicles and tanks, millions more artillery shells, and we must double our enabling capabilities, such as logistics, supply, transportation, and medical support.' Over time, that will lead to Europe carrying more of the burden for its own defense — and having more sway within the alliance. 'You now have a road map for Europeanizing NATO that you never had before, and that ultimately will lead to a more successful alliance,' Daalder said. 'Everybody wants to move in that direction, the U.S. and the Europeans.' Trump has long groused that the U.S. shoulders too much of the cost for defending the world and has pushed more than just NATO members to increase their defense budgets. The administration is also pressuring Japan, a non-NATO ally pursuing a new trade deal with Washington, to boost its defense spending significantly with the Pentagon describing the 5 percent benchmark as a new 'global standard.' It's a standard many countries may struggle to reach. Spain, far from the alliance's eastern flank, has been difficult to convince, as have other smaller countries such as Italy and Belgium that are still not hitting the 2 percent level the alliance adopted in 2014. Even Great Britain, one of Europe's biggest military powers, has balked at the 2032 deadline. Laying out a plan for boosting defense spending, Prime Minister Keir Starmer promised the U.K. would be at 2.5 percent by 2027 and expressed confidence about getting to 3 percent by 2034, at the latest. Paul McLeary contributed to this report.
Business Wire
4 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
